The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.

Back to full list of clinical trials

Ongoing clinical trials for cyclic vomiting: Actively recruiting


Condition:

Cyclic Vomiting

Study title:

Prospective Registry in Cyclic Vomiting Syndrome at MGH

Description of study:

The researchers are looking for people to take part in the Cyclic Vomiting Syndrome Prospective Registry Study.  They are exploring the causes, progression, and impact of the disease.

Basic eligibility criteria:

Diagnosed with CVS and 18 years of age or older

Principal Investigator:

Braden Kuo, MD

Contact:

Shahar Castel; 617-726-0196


Condition:

Cyclic Vomiting Syndrome

Study title:

Resting State Brain Response to Chronic Nausea and Cuff Pain

Description of study:

The proposed study will examine the CNS circuitry of nausea in the human brain. Results found from motion sickness studies in healthy adults will be applied to guide the analysis of brain physiology in patients suffering from chronic nausea, i.e. cyclic vomiting syndrome (CVS).

Basic eligibility criteria:

This study will aim to evaluate patients (n=25) diagnosed with CVS who are in an inter-ictal phase, i.e. at least 48 hours following cessation of any nausea/vomiting episode.

  1. Subjects age 18 to 80 years
  2. Diagnosis of Cyclic Vomiting Syndrome by Rome III criteria

EXCLUSION: Subjects who currently have an acute illness, those who are awaiting transplantation, and those who have a chronic illness, such as kidney failure, congestive heart failure, and diabetes. Use of prescription benzodiazepines within the previous 3 days, use of prescription opioids and self-reported use of cannabinoids within the previous 7 days are another exclusion criteria.
Another exclusion criterion is any nausea/vomiting episode within 48 hours prior to experimental session.

Principal Investigator:

Braden Kuo, MD

Contact:

Shahar Castel; 617-726-0196